Noveome Biotherapeutics

In a Pittsburgh lab, a drug that is really hundreds of drugs at once

Somewhere in a NICU, a premature baby weighs less than a bag of sugar. Her gut is failing - tissue dying faster than it can heal, a disease called necrotizing enterocolitis that surgeons can cut but rarely cure. A few hundred miles of supply chain away, in an office park off Alpha Drive, a 30-person company is manufacturing a clear fluid it believes can speak to that gut in its own language.

That fluid is ST266. It is not a single molecule with a single target, which is the entire pharmaceutical industry's preferred way of doing business. It is a secretome - the full collection of proteins and factors that a particular population of amnion-derived cells naturally pumps out. Noveome harvests the conversation, not the speaker.

This is a strange bet to make in 2026. Drug development rewards specificity - one target, one mechanism, one tidy story for regulators. Noveome decided the tidy story was the problem.

Inflammation rarely picks just one fight

Here is the inconvenient biology: the conditions that wreck the most lives - a dying infant gut, a brain after trauma, an eye losing its nerve, skin that won't close - are not caused by one rogue protein. They are cascades. Inflammation, cell death, and failed repair feed each other in a loop.

Aim a single-target drug at a cascade and you are bringing a key to a flood. It may fit a lock perfectly. The water does not care.

Noveome's founders noticed something the body already knew. During development, the amnion - the protective sac around a fetus - is a remarkably anti-inflammatory, pro-healing environment. The cells there secrete a coordinated mix of signals. Evolution, in other words, had already solved the multi-target problem. Nobody had thought to simply collect the answer and put it in a vial.

From "Stemnion" to Noveome - the rebrand was a confession

The company was founded in 2000 as Stemnion, Inc. The name told you what everyone assumed back then: the future was stem cells, and value lived in the cells themselves. For years that was the working theory.

Then the data nudged in a different direction. The therapeutic punch wasn't coming from transplanting cells - it was coming from what those cells secreted. So the company did the rare and slightly embarrassing thing a biotech can do: it admitted its original premise was incomplete, and renamed itself around the new one. Stemnion became Noveome. The cell stopped being the product. The secretome became it.

Backing that bet now is a board that does not look like a long shot. It includes Robert S. Langer of MIT - among the most cited engineers alive and a serial founder of companies that turned biology into medicine. When Langer lends his name to a secretome, the idea has graduated from interesting to investable.

Four numbers, one thesis: a quarter-century-old company still acting like its best chapter is the next one.

One biologic, taught to travel

ST266 has three jobs it does at once: calm inflammation, protect nerve cells, and help damaged tissue recover. What makes it unusually flexible is that Noveome can deliver it several ways depending on the wound - topically onto skin, intranasally toward the brain, or parenterally into the bloodstream. Same drug, different door.

What the money and the data actually say

Conviction is cheap in biotech. Capital and clean safety reviews are not. Noveome has both - a $51 million Series E from investors including MAK Capital, Lancet Capital, and Miraki Innovation, plus a Data Safety Monitoring Board that looked at the first cohort of treated infants and told the company to keep going.

The NEC trial is designed to enroll roughly 36 infants - about two-thirds receiving ST266 on top of standard care, the rest receiving standard care alone. It is small, deliberate, and aimed at one of neonatology's hardest problems. That is exactly the kind of trial where a multi-target biologic gets to prove it is more than a clever idea.

Mobilizing the wisdom to heal

Noveome's framing is unusually humble for a drug company. It doesn't claim to invent healing. It claims to mobilize a wisdom the body already carries - the coordinated repair signals present at the very start of a life - and point them at conditions where that repair has broken down.

There's a civic streak, too. The team is openly invested in turning Pittsburgh into a serious biotech hub, working alongside the region's hospitals and research institutions. A company treating the smallest patients in the city, trying to grow the city around it.

If the whisper works, it scales

The reason a NEC trial matters far beyond NEC is the platform underneath it. If a secretome can safely calm a cascade in the most fragile patients imaginable, the same logic extends to the eye, the brain, and the skin - anywhere inflammation, cell death, and failed repair run together. One manufacturing process, many indications. That is the dream Noveome is underwriting one cohort at a time.

It is also why skepticism is fair. Multi-target biologics are hard to characterize, hard to regulate, and hard to explain in a single sentence to a regulator who likes single sentences. Noveome has bet a quarter-century and $51 million that the biology is worth the difficulty.

Back in that NICU, the baby who weighs less than a bag of sugar is still the whole point. For years, the standard of care for her failing gut was to wait, support, and operate - and hope. Noveome is trying to add one option to that list: a vial of signals, drawn from the beginning of life, delivered drop by careful drop, while an independent board watches and so far keeps saying the same quiet word. Continue.